NCT06260059View on ClinicalTrials.gov

Efficacy Of Sodium Glucose Transporter Inhibitor (SGLT2I) In Adult Patients With Congenital Heart Disease

PHASE4RecruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

September 17, 2024

Primary Completion Date

December 31, 2026

Study Completion Date

June 1, 2027

Conditions
Adult Congenital Heart DiseaseHeart Failure
Interventions
DRUG

Empagliflozin 10 MG

Patient will be given 10 mg of Empagliflozin if randomized to the drug arm or will receive placebo drug for 1 year

DRUG

Placebo

To patients randomized to the placebo group, a placebo pill will be given

Trial Locations (3)

15213

RECRUITING

Magee Women's Hospital, Pittsburgh

RECRUITING

Presbyterian Hospital, Pittsburgh

15224

RECRUITING

Children's Hospital of Pittsburgh, Pittsburgh

All Listed Sponsors
collaborator

The Pittsburgh Foundation

OTHER

lead

Anita Saraf

OTHER

NCT06260059 - Efficacy Of Sodium Glucose Transporter Inhibitor (SGLT2I) In Adult Patients With Congenital Heart Disease | Biotech Hunter | Biotech Hunter